Programs
The Peptide Drugs We Discover
We screen for peptides across a range of disease areas in partnered collaborations and our internal programs
Cardiology - PPI Inhibition
Immunology - Enzyme Inhibition
Oncology - Enzyme Inhibition
Immunology | Oncology - T-cell targeting
Obesity - GPCR agonist
Our business model is simple – establish both internal discovery programmes and collaborative programmes with industry and academia.
We aim to balance the two through the efficiency that our technology enables and discover well characterised, selective drugs in diseases where a peptide drug makes sense.
